Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Petros PharmaceuticalsPTPI EV-to-EBITDA is 0.36 as of Jul. 23, 2026. Among 743 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 97.71% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Petros Pharmaceuticals's enterprise value is $-1.51 Mil.
Petros Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.21 Mil. Therefore, Petros Pharmaceuticals's EV-to-EBITDA for today is 0.36.
The historical rank and industry rank for Petros Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
PTPI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -67.24 Med: -1.21 Max: 64.98
Current: 0.36
During the past 7 years, the highest EV-to-EBITDA of Petros Pharmaceuticals was 64.98. The lowest was -67.24. And the median was -1.21.
PTPI's EV-to-EBITDA is ranked better than 97.71% of 743
companies
in the Drug Manufacturers industry
Industry Median: 13.02
vs PTPI: 0.36
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Petros Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Petros Pharmaceuticals's share price for today is $0.004.
Petros Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.156.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's EV-to-EBITDA falls into.
Petros Pharmaceuticals's current Enterprise Value is $-1.51 Mil.
Petros Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a EV-to-EBITDA of 0.36 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Petros Pharmaceuticals. According to the industry distribution chart, Petros Pharmaceuticals ranks #17 out of 743 companies in the Drug Manufacturers industry, placing it in the top 2.3%.
Is Petros Pharmaceuticals' EV-to-EBITDA too high?
Petros Pharmaceuticals' current EV-to-EBITDA is 0.36. The Drug Manufacturers industry median EV-to-EBITDA is 13.02. Petros Pharmaceuticals' value of 0.36 is 97.2% below this industry median. Based on the distribution chart, Petros Pharmaceuticals ranks #17 out of 743 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Petros Pharmaceuticals' EV-to-EBITDA compare to STEK and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #17 out of 743 companies for EV-to-EBITDA. This places Petros Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.02. Petros Pharmaceuticals' value of 0.36 is 97.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.02, based on 743 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Petros Pharmaceuticals's current EV-to-EBITDA of 0.36 is 97.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Petros Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current EV-to-EBITDA is 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current EV-to-EBITDA of 0.36. The current EV-to-EBITDA is 0.36 and 97.2% below the Drug Manufacturers industry median of 13.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current EV-to-EBITDA is 0.36 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 
